Evaluating the Maintenance of Efficacy and Tolerability when Transitioning from IV anti-CD20 Therapy to Ublituximab: ENHANCE Study Design, Patient Demographics and Preliminary Data

Download

site-sidebar-layout : default

ast-site-content-layout : default

site-content-style : default

site-sidebar-style : default

theme-transparent-header-meta : default

stick-header-meta : default

Drug Category : Array

Conference Category : Array

Lead Author : Foley J, et al.

Published Date : 11/10/2023

Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2023/10/Foley-ENHANCE-Study-Design_ECTRIMS-2023_-Poster_Final.pdf

Download Text :

Popup Confirmation? :

astra-migrate-meta-layouts : set